Bad news continues for CryoLife as tissue company forced to revise 2002 guidance
This article was originally published in Clinica
Executive Summary
CryoLife this week revised its guidance downwards for full year 2002, following adverse publicity surrounding its FDA warning letter and investigation (see Clinica No 1016, p 13). Vascular revenues for 2002 will be up 6-8% (compared with earlier predictions of low double-digit growth), and orthopaedics will show similar growth (down from 20%+), said CFO and vice-president Ashley Lee at the company's half-year results announcement. Cardiac revenues will be 4% up.